These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 15876257

  • 1. Long-term treatment with deferiprone in a L1 veteran.
    Meo A, Ruggeri A, La Rosa MA, Zanghì L, Kordes U, Fischer R.
    Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
    [Abstract] [Full Text] [Related]

  • 2. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A, Hussain T, Hussain S.
    J Ayub Med Coll Abbottabad; 2005 Dec; 17(4):12-5. PubMed ID: 16599026
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 5. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R.
    Haematologica; 2005 Oct; 90(10):1309-14. PubMed ID: 16219566
    [Abstract] [Full Text] [Related]

  • 6. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Oct; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 7. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Oct; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 8. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
    [Abstract] [Full Text] [Related]

  • 9. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 11. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
    Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ.
    Lancet; 2002 Aug 17; 360(9332):516-20. PubMed ID: 12241655
    [Abstract] [Full Text] [Related]

  • 12. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S.
    Am J Hematol; 2013 Apr 17; 88(4):251-60. PubMed ID: 23460233
    [Abstract] [Full Text] [Related]

  • 13. Deferiprone as an oral iron chelator in sickle cell disease.
    Voskaridou E, Douskou M, Terpos E, Stamoulakatou A, Meletis J, Ourailidis A, Papassotiriou I, Loukopoulos D.
    Ann Hematol; 2005 Jul 17; 84(7):434-40. PubMed ID: 15809885
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G.
    N Engl J Med; 1995 Apr 06; 332(14):918-22. PubMed ID: 7877649
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia.
    Zareifar S, Jabbari A, Cohan N, Haghpanah S.
    Arch Iran Med; 2009 Sep 06; 12(5):488-91. PubMed ID: 19722772
    [Abstract] [Full Text] [Related]

  • 19. Five-year trial of deferiprone chelation therapy in thalassaemia major patients.
    Taher A, Aoun E, Sharara AI, Mourad F, Gharzuddine W, Koussa S, Inati A, Dhillon AP, Hoffbrand AV.
    Acta Haematol; 2004 Sep 06; 112(4):179-83. PubMed ID: 15564727
    [Abstract] [Full Text] [Related]

  • 20. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Sep 06; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.